



Posting of Circular & Notice of GM

October 11, 2024

```
var wwwindow=((w.performance)[w.mozPerformance][w.msPerformance][w.webkitPerformance])(var d=document;AKSB=w.AKSB||{};AKSB.q=AKSB.q||{};AKSB.mark=AKSB.mark||function(e,...)(AKSB.q.push(["mark",e,...])(new Date).getTime()));AKSB.measure=AKSB.measure||function(e,...)(AKSB.q.push(["measure",e,...])(new Date).getTime()));AKSB.done=AKSB.done||function(e)(AKSB.q.push(["done",e]));AKSB.mark(["firstbyte",new Date).getTime());AKSB.prof=(custid:"793678",ustr:"",original:"0",clientrt:"1",ghostip:"23.220.107.8",ipv6:false,pct:"10",clientip:"34.233.115.68",requestid:"169cda4f",region:"41483",protocol:"",bver:"14.akM:"dscsa",akN:"ae",akTT:"O",akTX:"1",akTi:"169cda4f",ai:"501146",ra:"false",pmgn:"",pmgi:"",pmp:"",qc:""),function(e)(var _=d.createElement("script");_._async="async";_._src=e;var t=d.getElementsByTagName("script"),t=[t.length-1].parentNode.insertBefore(_,[t]({https:"==d.location.protocol?"https":"http:"})+("/ds-aksb-a.akamaihd.net/aksb.min.js"))
```

RNS Number : 9446H

Renalytix PLC

11 October 2024

Renalytix plc
(“Renalytix” or the “Company”)

**Posting of Circular
and
Notice of General Meeting**

LONDON and NEW YORK, 11 October, 2024 – Renalytix plc (LSE: REXX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, confirms that, further to the Company’s announcement released at 11:02 on 1 October 2024 (RNS Number: 4887G), the Circular, containing the Notice of the General Meeting, which sets out the Resolutions and further details on the Fundraising, has been posted to Shareholders and is available on the Company’s website at <https://renalytix.com>.

The General Meeting to approve the Resolutions will be held at 6 Stratton Street, Mayfair, London, W1J 8LD at 12.00 noon on 31 October 2024.

The Circular includes a unanimous Board recommendation that all Shareholders of the Company vote in favour of the Resolutions.

For further information, please contact:

Renalytix Plc www.renalytix.com
James McCullough, CEO **Via Walbrook PR**

Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) **Tel: 020 7710 7600**
Nicholas Moore / Nick Harland / Ben Good

Oberon Capital (Joint Broker and Sole Bookrunner) **Tel: 020 3179 5300**
Mike Seabrook / Nick Lovering / Jessica Cave

Walbrook PR Limited **Tel: 020 7933 8780** or renalytix@walbrookpr.com
Paul McManus / Alice Woodings **Mob: 07980 541 893 / 07407 804 654**

CapComm Partners **Tel: 415-389-6400** or investors@renalytix.com
Peter DeNardo

*The person responsible for making this Announcement on behalf of the Company is
James McCullough, Chief Executive Officer.*

About Renalytix plc
Renalytix (LSE: REXX) (OTCQB: RNLXY) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lsegroup.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](http://www.rns.com/privacy).

END

NOGKZMMGKMZGDZM